Pfizer stock steadies after Q2 2026 beat and modest guidance lift

Pfizer Inc. (US7170811035) stock is holding in the mid-$26 range as of August 13, 2026, after the company delivered a solid Q2 2026 earnings beat and raised its full-year revenue guidance while keeping its EPS outlook intact. Per a detailed Q2 2026 earnings overview dated August 13, 2026, Pfizer reported revenue of $15.03 billion for the quarter ended June 30, 2026, topping consensus expectations and signaling modest year-over-year growth in its diversified portfolio. An accompanying analysis of the same report highlights adjusted EPS of $0.77 for Q2 2026, ahead of the street estimate, and confirms that management slightly raised the midpoint of its 2026 revenue guidance to $61.5 billion while reiterating full-year adjusted EPS guidance at $2.90.

Q2 2026 beat with revenue and EPS outperformance

Per an August 13, 2026 breakdown of Pfizer's second quarter 2026 results, revenue for the quarter came in at $15.03 billion, exceeding consensus estimates of $14.4 billion and marking 2.6 percent year-over-year growth versus the prior-year quarter. One Q2 2026 earnings highlights article notes that this revenue performance represented a 4.4 percent beat versus analyst expectations, underlining that Pfizer's core franchise is delivering incremental growth even as COVID-related sales moderate. A separate August 13, 2026 metrics-focused review confirms the same $15.03 billion Q2 2026 revenue figure and restates the 2.6 percent annual growth rate, reinforcing the sense that topline momentum is modest but positive.

On the bottom line, adjusted EPS for Q2 2026 was $0.77, as cited in the August 13, 2026 earnings highlight article, compared with analyst estimates of $0.68 for the period, implying an earnings surprise of roughly nine cents per share. The same overview points out that this $0.77 adjusted EPS figure represented a beat of 12.9 percent versus consensus, even though it was fractionally below the $0.78 adjusted EPS reported in the year-ago quarter. An August 13, 2026 analysis focusing on estimates aligns with this view, noting EPS of $0.77 for the quarter ended June 2026 against a consensus forecast of $0.68 and emphasizing that the company delivered an EPS surprise of just over 13 percent. Together, these figures confirm that Pfizer's Q2 2026 profitability modestly outpaced expectations despite a nearly flat comparison with the prior-year result.

Operationally, the Q2 2026 earnings discussion highlights that Pfizer's operating margin stood at 27.9 percent for the quarter ended June 30, 2026, essentially in line with the same quarter of the previous year. The same article notes that organic revenue rose 1 percent year over year in Q2 2026, underscoring that underlying growth excluding certain one-off factors is limited but positive. For investors comparing these metrics, the combination of a 2.6 percent total revenue increase, 1 percent organic growth, and an operating margin near 28 percent suggests a company that is stabilizing after a post-pandemic reset rather than returning to the hyper-growth phase seen during peak COVID product demand.

Guidance raised, consensus trends and valuation context

In the guidance section of the August 13, 2026 Q2 2026 overview, Pfizer's management is reported to have slightly lifted the midpoint of its full-year 2026 revenue guidance to $61.5 billion from the prior $61.0 billion. The same piece underscores that this half-billion-dollar upward adjustment is tied primarily to stronger-than-expected performance in non-COVID products, with the company attributing roughly $1.5 billion of the guidance improvement to its non-COVID portfolio when considering gross effects. Importantly, management reiterated full-year adjusted EPS guidance at $2.90 at the midpoint, signaling confidence that margin dynamics and cost controls can sustain earnings even as the sales mix shifts away from pandemic-related products.

An August 12, 2026 sector-focused analysis of Pfizer's second quarter 2026 results dives deeper into the portfolio mix behind this guidance update. It notes that revenues excluding Comirnaty and Paxlovid increased 5 percent operationally in Q2 2026, while launched and acquired products delivered 18 percent operational growth. A non-COVID portfolio analysis emphasizes that Pfizer raised the midpoint of its 2026 revenue guidance by $500 million, with roughly $1.5 billion of the improvement effectively tied to better-than-expected performance of non-COVID drugs across key therapeutic areas. For investors, the quantified shift toward non-COVID revenue, with a 5 percent operational increase in those lines and high-teens growth in launched and acquired assets, reinforces the thesis that Pfizer's next phase of growth will depend more on traditional and newly acquired medicines than on pandemic vaccines or antivirals.

Consensus expectations for Pfizer's earnings trajectory also show incremental improvement around the time of these Q2 2026 results. An August 12, 2026 earnings outlook summary indicates that the consensus estimate for 2026 EPS has ticked up from $2.96 per share to $2.97 per share over the past 60 days, while the 2027 EPS consensus has risen from $2.86 per share to $2.93 per share in the same period. This pattern suggests that analysts are modestly revising their medium-term projections higher as they incorporate stronger non-COVID performance and the updated guidance. The same analysis compares Pfizer's valuation to its industry peers, noting that the shares trade at 9.03 times forward earnings, versus 18.91 times for the broader industry and slightly below the stock's own five-year mean multiple of 9.28. That relative discount, paired with a stabilized earnings outlook, is likely to feature prominently in many investors' valuation discussions.

Alongside these forward-looking metrics, dividends remain a significant part of the Pfizer investment story. A late August 12, 2026 valuation article cites proprietary intrinsic value estimates around $26.53 per share and observes that the current market price near $26.31 implies the stock is undervalued by 0.8 percent on that measure, while the dividend yield stands above 6 percent. Though dividend growth is not the primary near-term catalyst in the latest earnings commentary, the combination of a very high single-digit yield, a forward P/E below its industry average, and incremental improvements in non-COVID profitability helps explain why some income-oriented investors continue to pay close attention to the stock despite only modest near-term growth.

Market reaction: price levels and recent trading range

On the market side, multiple quote services provide a snapshot of Pfizer's share price behavior around the Q2 2026 earnings release and its aftermath. A live quote page updated on August 13, 2026 shows Pfizer shares trading at $26.70, with a market capitalization of $161.82 billion based on that price. The same quote indicates that on August 13, 2026, the stock traded between an intraday low of $26.36 and a high of $26.70, with the current price of $26.70 standing 1.3 percent above the day's low. For context, this positioning suggests the shares are hovering close to the intraday high, reflecting a steady rather than volatile reaction following the earnings beat and guidance adjustment.

Another price snapshot taken just ahead of the August 13, 2026 regular session displays a delayed quote of $26.37 for Pfizer, with a prior close of $26.31 on August 12, 2026 and a one-day move of negative 1.16 percent at that close. A delayed quote overview notes pre-market trading volume of 77,730 shares and confirms the $26.31 closing price, illustrating how the stock has been oscillating within a narrow band around the mid-$26 area. A broader performance summary from August 13, 2026 adds that Pfizer shares are now trading at $26.29 based on the August 12, 2026 closing price and have increased 5.6 percent since a prior period benchmark, suggesting a modest recent rebound even if the shares remain far below their pandemic-era highs.

Year-to-date performance also reflects this cautious recovery pattern. An August 12, 2026 industry comparison points out that Pfizer's stock has risen 6.8 percent so far in 2026, compared with a 13.5 percent gain for the healthcare industry as a whole. For investors, the numbers illustrate that while Pfizer is again moving higher, it is doing so at roughly half the pace of the broader peer group. This combination of lagging industry performance, a relatively low forward earnings multiple, and a high dividend yield provides part of the context for recent commentary that characterizes the shares as more income-oriented than aggressively growth-driven at the current stage of the cycle.

Intraday and short-term movements around the Q2 2026 print also show a restrained reaction. The August 13, 2026 Q2 highlights article notes that Pfizer's stock traded at $26.97 in a recent post-earnings snapshot, up from $25.03 just before the release, indicating a move of roughly $1.94 or close to 7.7 percent in the days surrounding the report. That difference between the pre-earnings level and the subsequent trading price signals that the market did reward the company's beat and guidance increase, but the share price has since settled closer to the mid-$26 zone as of the morning of August 13, 2026. For tactical traders, the $25.03 pre-earnings reference point and the $26.70 current level frame a recent range in which the shares climbed but did not break out to new intermediate highs.

Non-COVID portfolio and pipeline as growth drivers

Beyond the headline numbers, pipeline and portfolio details from the August 12, 2026 non-COVID analysis highlight why management and analysts are focusing more on the breadth of Pfizer's medicines. The same discussion notes that revenues excluding Comirnaty and Paxlovid rose 5 percent operationally in Q2 2026, bringing attention to core categories such as oncology, vaccines outside COVID, cardiometabolic drugs, and immunology. Launched and acquired products grew 18 percent operationally in Q2 2026, a figure that illustrates how newer assets are contributing a disproportionately large share of incremental growth. For investors, the 18 percent operational growth statistic matters because it suggests that strategic acquisitions and recently launched therapies are starting to scale, helping offset the decline in pandemic-related sales.

The article also explains that the roughly $1.5 billion improvement tied to non-COVID products in the updated 2026 guidance reflects a mix of volume growth and better-than-expected pricing and uptake across several therapeutic franchises. Although individual product contributions are not quantified in full detail in the available snippets, the aggregate effect is clear: newer and non-pandemic medicines are now driving the guidance upgrade, while COVID-related products are a smaller and more volatile portion of the business. That shift has implications for future quarters, because a portfolio diversified across chronic and specialty therapies is typically viewed as more predictable than one heavily reliant on episodic public-health demand.

In the context of this evolving mix, one representative Pfizer product that demonstrates the company's strategic emphasis on infectious disease prevention is the pneumococcal conjugate vaccine Prevnar 20. According to Pfizer's own product materials, Prevnar 20 is approved for helping protect adults and certain pediatric populations against invasive pneumococcal disease and pneumonia caused by Streptococcus pneumoniae. The broader Q2 2026 discussion of non-COVID revenues implicitly includes vaccines like Prevnar 20 in the pool of products that benefit from healthcare providers' renewed focus on routine immunization. For long-term shareholders, continued uptake of vaccines such as Prevnar 20 and similar portfolio assets is one of the practical ways the company aims to support stable cash flows beyond the COVID cycle.

Product spotlight: Prevnar 20 as a key vaccine franchise

Prevnar 20, Pfizer's 20-valent pneumococcal conjugate vaccine, illustrates how the company leverages established platforms to broaden coverage against infectious diseases. The vaccine builds on the legacy of earlier Prevnar versions by targeting additional pneumococcal serotypes associated with invasive disease and pneumonia. In adult populations, it is indicated for the prevention of pneumococcal pneumonia and invasive disease caused by the 20 serotypes included in the vaccine, while pediatric indications aim to reduce the incidence of serious infections such as bacteremia and meningitis as national immunization programs evolve. For Pfizer's revenue mix, vaccines like Prevnar 20 play an important role because they can generate recurring demand as part of routine healthcare rather than relying on episodic pandemic waves.

Commercial data referenced in Pfizer's broader portfolio commentary suggest that the company's vaccine franchise benefits from demographic and policy trends supporting adult immunization, including the aging of populations and public-health initiatives focused on preventing hospitalizations among high-risk groups. When combined with other vaccines and specialty medicines, Prevnar 20 helps maintain a foundation of relatively predictable, guideline-driven demand. This type of product profile is particularly significant in the current environment, where investors are evaluating how quickly Pfizer can transition from a pandemic-centric revenue base to a more traditional diversified pharma footprint.

Pfizer stock and investor takeaway

As of the early trading hours on August 13, 2026, Pfizer stock on the NYSE is quoted around $26.70, within a daily range of $26.36 to $26.70, and the company carries a market capitalization of roughly $161.82 billion based on that quote. Recent closing data from August 12, 2026 show the shares finishing at $26.31, down 1.16 percent for that session, while performance summaries indicate a 5.6 percent rise over a selected recent period and a 6.8 percent gain year to date relative to a 13.5 percent industry advance. For investors, the core numbers from Q2 2026 - $15.03 billion in revenue with 2.6 percent year-over-year growth, adjusted EPS of $0.77 that beat consensus by more than 10 percent, and a modest guidance lift to $61.5 billion with EPS still targeted at $2.90 - frame a story of incremental progress rather than dramatic change. The shares currently combine that steady fundamental backdrop with a forward P/E multiple near 9, lower than industry averages, and a dividend yield in the mid-single digits, positioning Pfizer as a large-cap healthcare name where income and valuation play as much of a role as earnings surprises in the investment case.

Go deeper

More on Pfizer stock and its Q2 2026 earnings context

Investor Relations

Further details on Pfizer's corporate strategy, pipeline and financial disclosures are available via the company's own investor materials.

Fact box

Company: Pfizer Inc.

ISIN: US7170811035

Ticker: PFE

Exchange: NYSE

Price (as of August 13, 2026, 8:40 a.m. ET): $26.37 USD

Market cap: $161.82 billion (as of August 13, 2026)

Sector / Industry: Health care / Pharmaceuticals

Index membership: S&P 500